Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;51(7):1615-1627.
doi: 10.1002/eji.202048922. Epub 2021 May 31.

JAK inhibitors: Ten years after

Francesca Romana Spinelli  1 , Françoise Meylan  2 , John J O'Shea  3 , Massimo Gadina  2
Affiliations
Free article
Review

JAK inhibitors: Ten years after

Francesca Romana Spinelli et al. Eur J Immunol. 2021 Jul.
Free article

Abstract

The European Journal of Immunology was launched 50 years ago, coinciding with the discovery of many cytokines and growth factors and the emergence of an entirely new field of research. Ultimately, our knowledge about the biological activity of these factors allowed us to better understand how the immune system functions in the context of inflammatory and autoimmune diseases leading to the development of targeted biologic therapies. The study of cytokine signal transduction led to the discovery of Janus kinases (JAK), and the consideration of therapeutically targeting JAKs to treat immune and inflammatory diseases. This year also marks the tenth anniversary of the approval of the first JAK inhibitor (jakinib) and now there are a total of nine approved jakinibs for treatment of rheumatologic, dermatologic, gastrointestinal, and neoplastic indications and most recently COVID-19. Here, we summarized the discoveries that led to development of first-generation jakinibs, discussed some of the newer, possibly more selective jakinibs, as well as jakinibs that also target other kinases. We also illustrated the rationale behind the application of these drugs in the treatment of COVID-19 cytokine storm. In this review, we will discuss the clinical success of jakinibs, the gaps in our understanding of their biological activities as well as challenges in regard to their clinical application.

Keywords: Autoimmunity; COVID-19; Cytokines; Janus Kinase; Kinase Inhibitors.

PubMed Disclaimer

References

    1. Burmester, G. R., Bijlsma, J. W. J., Cutolo, M. and McInnes, I. B., Managing rheumatic and musculoskeletal diseases-past, present and future. Nat. Rev. Rheumatol. 2017. 13: 443-448.
    1. Monaco, C., Nanchahal, J., Taylor, P. and Feldmann, M., Anti-TNF therapy: past, present and future. Int. Immunol. 2015. 27: 55-62.
    1. Darnell, J. E., Jr., Kerr, I. M. and Stark, G. R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994. 264: 1415-1421.
    1. Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T. S. et al., Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995. 270: 797-800.
    1. Kreins, A. Y., Ciancanelli, M. J., Okada, S., Kong, X. F., Ramirez-Alejo, N., Kilic, S. S., El Baghdadi, J. et al., Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 2015. 212: 1641-1662.

Publication types

MeSH terms